Partnering
Partnering with CellMosaic®
Conjugate drug development is currently one of the fastest-growing and most promising sectors in the life science industry. Historically, the technical barriers to entering this field have been significant. To capitalize on this opportunity, a successful company must have robust conjugation processes and innovative linkers or polymers in place. With few players and limited technologies available in the market, many companies seek collaborations or licensing deals to develop conjugate drugs.
CellMosaic began developing its conjugation-based platform in 2008 and has since performed numerous conjugations involving a wide variety of molecules. AqT® linkers stand out as some of the most hydrophilic and versatile linkers in development. We can efficiently synthesize any AqT® molecule with superior properties for conjugate drug development. The flexibility in AqT® molecules is unmatched by any existing linker or polymer technologies, thanks to the versatile nature of sugar alcohol and the modularity of their chemistry. Additionally, our advanced conjugation processes and adaptable AqT® architectures allow us to explore opportunities beyond the ADC field for target-specific drug delivery. With exclusive patents on AqT® molecules and our cutting-edge conjugation processes, CellMosaic is well-positioned to collaborate and partner with other companies in the development of AqT® conjugate drugs.
AqT® ADC Development & Manufacturing
Other AqT® Drug Conjugate Development
Contact us to learn how the AqT® platform can potentially advance your program. If you'd like to schedule a call to discuss further, click the button below to choose a convenient time.
